Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

Dr Marjorie Green, head of global clinical development, oncology, at Merck Research Labs, said the subcutaneous route "has the potential to improve the patient experience as well as increase ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Based in France, Mathilde Lecoupeur is the Corporate Poultry Vaccination Services Manager for IB and IBD at Ceva. In her role, she drives strategy in more than 47 countries and oversees field trials.

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...

Intramuscular and subcutaneous routes of administration of relevant licensed vaccines were considered for inclusion. We excluded intradermal, intranasal and AS03-adjuvanted vaccines, which are not ...

Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the ...

The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...